Correlation Between Uniper SE and Sartorius Stedim

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Uniper SE and Sartorius Stedim at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Uniper SE and Sartorius Stedim into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Uniper SE and Sartorius Stedim Biotech, you can compare the effects of market volatilities on Uniper SE and Sartorius Stedim and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Uniper SE with a short position of Sartorius Stedim. Check out your portfolio center. Please also check ongoing floating volatility patterns of Uniper SE and Sartorius Stedim.

Diversification Opportunities for Uniper SE and Sartorius Stedim

0.29
  Correlation Coefficient

Modest diversification

The 3 months correlation between Uniper and Sartorius is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Uniper SE and Sartorius Stedim Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sartorius Stedim Biotech and Uniper SE is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Uniper SE are associated (or correlated) with Sartorius Stedim. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sartorius Stedim Biotech has no effect on the direction of Uniper SE i.e., Uniper SE and Sartorius Stedim go up and down completely randomly.

Pair Corralation between Uniper SE and Sartorius Stedim

Assuming the 90 days trading horizon Uniper SE is expected to under-perform the Sartorius Stedim. But the stock apears to be less risky and, when comparing its historical volatility, Uniper SE is 1.12 times less risky than Sartorius Stedim. The stock trades about -0.01 of its potential returns per unit of risk. The Sartorius Stedim Biotech is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  18,245  in Sartorius Stedim Biotech on October 9, 2024 and sell it today you would earn a total of  863.00  from holding Sartorius Stedim Biotech or generate 4.73% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Uniper SE  vs.  Sartorius Stedim Biotech

 Performance 
       Timeline  
Uniper SE 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Uniper SE has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Sartorius Stedim Biotech 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Sartorius Stedim Biotech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Sartorius Stedim may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Uniper SE and Sartorius Stedim Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Uniper SE and Sartorius Stedim

The main advantage of trading using opposite Uniper SE and Sartorius Stedim positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Uniper SE position performs unexpectedly, Sartorius Stedim can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sartorius Stedim will offset losses from the drop in Sartorius Stedim's long position.
The idea behind Uniper SE and Sartorius Stedim Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Money Managers
Screen money managers from public funds and ETFs managed around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments